DE69912279D1 - 5-ht1f agonisten - Google Patents

5-ht1f agonisten

Info

Publication number
DE69912279D1
DE69912279D1 DE69912279T DE69912279T DE69912279D1 DE 69912279 D1 DE69912279 D1 DE 69912279D1 DE 69912279 T DE69912279 T DE 69912279T DE 69912279 T DE69912279 T DE 69912279T DE 69912279 D1 DE69912279 D1 DE 69912279D1
Authority
DE
Germany
Prior art keywords
ht1f agonists
ht1f
agonists
mammal
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69912279T
Other languages
English (en)
Other versions
DE69912279T2 (de
Inventor
Ann Filla
James Koch
Michael Mathes
Patrick Rocco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69912279D1 publication Critical patent/DE69912279D1/de
Publication of DE69912279T2 publication Critical patent/DE69912279T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69912279T 1998-06-30 1999-06-25 5-ht1f agonisten Expired - Fee Related DE69912279T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9119898P 1998-06-30 1998-06-30
US91198P 1998-06-30
PCT/US1999/014400 WO2000000487A1 (en) 1998-06-30 1999-06-25 5-ht1f agonists

Publications (2)

Publication Number Publication Date
DE69912279D1 true DE69912279D1 (de) 2003-11-27
DE69912279T2 DE69912279T2 (de) 2004-07-29

Family

ID=22226571

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69912279T Expired - Fee Related DE69912279T2 (de) 1998-06-30 1999-06-25 5-ht1f agonisten

Country Status (9)

Country Link
US (1) US6358972B1 (de)
EP (1) EP1089993B1 (de)
JP (1) JP2002519348A (de)
AT (1) ATE252572T1 (de)
AU (1) AU4831899A (de)
CA (1) CA2336254A1 (de)
DE (1) DE69912279T2 (de)
ES (1) ES2209462T3 (de)
WO (1) WO2000000487A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696439B1 (en) * 1999-02-26 2004-02-24 Eli Lilly And Company 5-HT1F agonists
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2002024681A2 (en) * 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h-吲唑化合物
JP2005526691A (ja) * 2001-08-08 2005-09-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 治療剤1H−ピリド[4,3−b]インドール
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
CN1777584A (zh) 2003-04-18 2006-05-24 伊莱利利公司 作为5-ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
JP2007516266A (ja) 2003-12-17 2007-06-21 イーライ リリー アンド カンパニー 5−ht1fアゴニストとしての置換(4−アミノシクロヘキセン−1−イル)フェニルおよび(4−アミノシクロヘキセン−1−イル)ピリジニル化合物
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
US7375219B2 (en) 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
AR060451A1 (es) 2006-04-13 2008-06-18 Neuraxon Inc Compuestos de indol 1,5 y 3,6-sustituidos con actividad inhibitoria de nos
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
PL2276732T3 (pl) 2008-04-16 2015-11-30 Karobio Ab Nowe ligandy receptora estrogenowego
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ikk2阻害剤としてのインドール誘導体
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
CA2819373A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
US9321756B2 (en) 2011-03-22 2016-04-26 Amgen Inc. Azole compounds as PIM inhibitors
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
SG11201706515QA (en) 2015-02-11 2017-09-28 Sunovion Pharmaceuticals Inc 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
EP3661929B1 (de) 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochromanverbindungen und verwendungen davon
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
TWI829107B (zh) 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體,以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
EP0494774A1 (de) 1991-01-11 1992-07-15 MERCK SHARP & DOHME LTD. Indazol-substituierte 5-Kettenglieder heteroaromatische Verbindungen
TW263508B (de) * 1991-02-12 1995-11-21 Pfizer
GB9226537D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
ATE252572T1 (de) 2003-11-15
EP1089993B1 (de) 2003-10-22
DE69912279T2 (de) 2004-07-29
JP2002519348A (ja) 2002-07-02
WO2000000487A1 (en) 2000-01-06
CA2336254A1 (en) 2000-01-06
US6358972B1 (en) 2002-03-19
EP1089993A1 (de) 2001-04-11
ES2209462T3 (es) 2004-06-16
AU4831899A (en) 2000-01-17

Similar Documents

Publication Publication Date Title
DE69912279D1 (de) 5-ht1f agonisten
NO2017022I1 (no) Obeticholinsyre
DE60036924D1 (de) 5-ht1f agonisten
ATE273305T1 (de) Thrombin-inhibitoren
EA200200619A1 (ru) Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
DK0850221T3 (da) Meta-guanidin-, urinstof-, thiourinstof- eller azacykliske aminobenzoesyrederivater som intergrinantagonister
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
EA200000871A1 (ru) Ингибиторы фосфолипазных ферментов
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
TNSN02008A1 (fr) Derives d'acides isophtalique nouveaux inhibiteurs de mmp, et compositions les contenant
ATE284879T1 (de) Indazol-derivate als 5-ht1f agonists
BR0313846A (pt) Derivados de dioxano-2-alquilcarbamatos, sua preparação e sua aplicação em terapêutica
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
ES2011919A6 (es) Metodo para producir compuestos antagonistas de los leucotrienos.
WO2000000490A3 (en) 5-ht1f agonists
TR200103680T2 (tr) IL-8 reseptör antagonistleri.
HU9800970D0 (en) Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
NO20014127L (no) 5-HT1F agonister
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
DE69524064D1 (de) Indan-2-mercaptoacetylamid disulfidderivate als enkephalinase inhibitoren
YU43499A (sh) Kristalna hidratovana natrijumova so (e)-4,6-dihloro-3- (2-okso-1-fenilpirolidin-3-iliden metil)-1h-indol-2- karboksilne kiseline
MY134147A (en) Method for stoping hysteresis

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee